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ABSTRACT The objectives of this study were to investi-
gate whether oral supplementation of L-2-oxothiazolidine-
4-carboxylate (OTC) is effective for increasing tissue
glutathione (GSH) concentrations in rats fed a diet very
low (0.5%) in protein - a model of wasting malnutrition -
and to determine the efficacy of OTC for protection
against pulmonary oxygen toxicity Weanling rats, fed a
0.5 or 15% protein diet for 2 wk, were given an oral sup-
plement of OTC, and tissue GSH concentrations were
measured over a 24 h period OTC supplementation to
rats fed 0.5% protein significantly increased GSH con-
centrations in liver and lung, but not in kidney and
blood, when compared with the 0.5% protein unsupple-
mented group. The liver GSH concentration in the 0.5%
protein OTC-supplemented group was higher than the
15% control group. Daily supplementation of OTC pro-
tected rats from pulmonary oxygen toxicity during 4 days
of 85% oxygen exposure as determined by lung-to-body
weight ratios and in vivo proton magnetic resonance im-
aging. Although hyperoxia exposure increased lung GSH
concentrations in all groups, OTC supplementation was
effective for increasing lung GSH concentration in rats
fed the 0.5% protein diet. This study demonstrated that
oral administration of OTC to wasting malnourished rats
is an effective procedure to increase GSH concentration
rapidly in target organs such as lung, and that daily sup-
plementation of a low dose of OTC has a sustained effect
to protect against pulmonary oxygen toxicity during
4 days of hyperoxia exposure.-Taylor, C. G.; Bauman,
P. F., Sikorski, B., Bray, T. M. Elevation of lung gluta-
thione by oral supplementation of L-2-oxothiazolidine-4-
carboxylate protects against oxygen toxicity in protein
energy malnourished rats. FASEBJ 6: 3101-3107; 1992.
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GLUTATHIONE (GSH,’ ‘y-GLUTAMYLCYSTEINYLGLYCINE), a sub-
strate for GSH transferase and GSH peroxidase, plays im-
portant roles in cellular defense against xenobiotic com-
pounds, reactive oxygen species, and free radicals (1). The
concentration of GSH in various tissues reflects the potential
for detoxification in the body. For example, depletion of
GSH with diethyl maleate increases the toxicity of many
xenobiotics whereas treatment with cysteine, methionine, or
N-acetylcysteine, precursors for GSH synthesis, decreases
their toxicity (1). Tissue GSH concentrations can be
influenced by dietary manipulation, e.g., hepatic GSH is
decreased during fasting or by feeding diets low in protein
or limiting in sulfur amino acids (2, 3).
Wasting malnutrition is a worldwide problem. Protein
energy malnutrition (PEM) affects millions of children in
developing countries. In affluent countries, a large number
and variety of patients also suffer PEM secondary to, for ex-
ample, burns, chronic digestive diseases, alcoholism, AIDS,
or cancer (4, 5). Decreases in tissue and blood GSH concen-
trations occur in malnutrition (6) and are associated with an
increased toxicity to drug or hyperoxia therapy (7, 8). En-
hancing detoxification by the antioxidant defense system
during the early stabilization phase of the rehabilitation of
wasted patients is becoming recognized as being important
to the survival of the most debilitated subjects (9).
Prolonged high concentration oxygen therapy is often
used with infants of low birth weight (LBW) to increase their
chance of survival (10). Several factors, including precarious
nutritional status and a compromised antioxidant defense
system, may contribute to the high morbidity of these infants
(11). Rapid and noninvasive procedures for establishing the
defense system in LBW infants are also required at the early
stabilization stage.
Cysteine is the limiting amino acid for GSH synthesis,
and hepatic GSH responds to the availability of cysteine and
cysteine precursors in the diet (3). However, it is difficult to
supplement cysteine because cysteine can be toxic and is
rapidly oxidized to cystine, which has low solubility at neu-
tral pH (12, 13). L-2-Oxothiazolidine-4-carboxylate (OTC),
a stable derivative of cysteine, is converted intracellularly to
cysteine by the enzyme 5-oxoprolinase (14). Oral administra-
tion of OTC is able to elevate hepatic GSH in protein-
deficient rats within 4 h (15). Thus, the objectives of this
study are: 1) to test the hypothesis that oral OTC supplemen-
tation is effective for increasing tissue GSH concentrations,
especially in the lung, in rats fed a very low protein (0.5%)
diet as a model of wasting malnutrition, and 2) to determine
the efficacy of OTC for protecting PEM rats from pulmonary
oxygen toxicity.
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MATERIALS AND METHODS
Chemicals
5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB), NADPH, GSH
reductase (type III from yeast), and OTC were obtained
from Sigma Chemical (St. Louis, Mo.). GSH was obtained
from Boeringer-Manheim Canada (Dorval, Quebec). All
other chemicals were obtained from Fisher Scientific
(Toronto, Ontario).
Animals and diets
The animal care protocol for experiments conducted in this
paper was reviewed and approved by the University of
Guelph Animal Care Committee. Male weanling Wistar rats
(Charles River Canada, St. Constant, Quebec) with initial
weight of 55-65 g were housed individually in suspended
stainless steel mesh cages in a temperature- and humidity-
controlled room with light from 0800 to 2000 h. Rats had
free access to casein-based purified diets containing either
0.5 or 15% protein (Table 1) for 2 wk.
Experimental design
In the first experiment, the effect of oral supplementation of
OTC on tissue GSH concentration over 24 h was studied in
rats fed 0.5 or 15% protein diet for 2 wk. Before OTC sup-
plementation, feed was removed during the light period. At
the beginning of the dark period (time 0) and 4 and 8 h later,
each rat was given by gavage either O’RJ (0.035 g dissolved
in 0.5 ml water) or vehicle (water). The dose of OTC was
chosen such that rats fed the 0.5% protein diet would receive
an amount of sulfur amino acid equivalent to the amount
available to rats fed the 15% protein diet, taking into account
the average amount of feed consumed and the methionine
and cyst(e)ine content of the diet. Feed was returned at time
0 and was available during the entire 24 h experimental
period. Rats were killed by CO2 intoxication, followed by
decapitation beginning at time 0 and every 4 h for 24 h.
Liver, lung, and kidney were removed, frozen in liquid nitro-
gen, and stored at - 80#{176}Cuntil analysis. Trunk blood was
collected in heparinized tubes and 50 tl was immediately ali-
quoted into 1 ml 5% trichloroacetic acid, centrifuged, and
the supernatant fraction was stored frozen at - 80#{176}Cuntil
analysis for total GSH.
To study the effect of oral supplementation of OTC on pul-
monary oxygen toxicity, a similar design was carried out in
the second experiment. At the end of a 2 wk feeding regi-
men, each dietary treatment group (0.5 or 15% protein) was
TABLE 1. Diet composition
Ingredient
Dietary protein, gilOO g
0.5% 15%
Casein 0.59 17.6
DL-methionine 0.01 0.30
Cornstarch’ 84.7 67.4
Corn oil’ 5.0 5.0
Cellulose’ 5.0 5.0
Vitamin mix’ 1.0 1.0
Mineral mix1 3.5 3.5
Choline bitartrate 0.2 0.2
Casein-Vitafree [85.2% protein on air-dried basis, protein
contains 2.5% methionine and 0.3% cystine (U.S. Biochemical product
information)1, U.S. Biochemical (USB), Clevelnd, Ohio. USB.
‘St. Lawrence Starch, Mississauga, Ontario. Celufil-non-nutritive
bulk, USB. ‘AIN-76A (16, 17). AIN-76 (17).
given a daily supplement of OTC (0.035 g in 0.25 ml water)
or vehicle for 4 days during the hyperoxia exposure. OTC
supplementation and the hyperoxia exposure started at the
beginning of the dark period (time 0). Rats were exposed to
85% oxygen or air for 4 days in Plexiglas chambers. The
chambers were opened once per day for approximately
15 mm to supply fresh feed and administer OTC or vehicle.
For 85% oxygen chamber, compressed oxygen and air were
mixed with a Bird 3800 Microblender, and the oxygen con-
centration was monitored continuously using a Servomex
Oxygen Analyzer 0A570. The air flow rate for both cham-
bers was controlled at 8-10 chamber changes/h.
GSH assay
Tissue was homogenized in 5% trichloroacetic acid for 10 s
(Ultra Turrax disperser with stainless steel shaft, Terochem
Laboratories, Mississauga, Ontario) and centrifuged at
10,000 x g for 15 mm at 4#{176}C.The supernatant fraction was
analyzed for total GSH by the enzymatic method of Tietze
(18). The formation of a conjugate with DTNB was mea-
sured at 412 nm.
Assessment of lung damage
To assess the severity of hyperoxia-induced lung damage,
lung-to-body weight ratios, in vivo proton magnetic reso-
nance imaging (MRI), and histopathology were used. Rats
were imaged by in vivo proton MRI on day 0 and after
4 days of hyperoxia exposure using a SIS 2.0 tesla/31 cm
bore imaging system (Spectroscopy Imaging Systems Corpo-
ration, Fremont, Calif.). For the imaging sequences, a
respiratory gating device was used to trigger data acquisition
and thus eliminate motion artifacts. Multiple proton image
slices were taken in the transverse plane using an echo time
(TE) of 25 ms and a delay time (TR) of 1.0 s. The image
slices were 2.4 mm thick, field of view was 8 x 6 cm2 with
128 phase-encoding steps, 4 acquisitions per step, and had
512 frequency encoding points. To verify that the high-
intensity proton signal in the lung region of the images
represented protons in water molecules and not lipid ac-
cumulation, localized spectra (4.7 x 4.7 mm3 voxels) were
obtained using the volume-selective spectroscopy (VOSY)
technique (19, 20). The sequence for the VOSY determina-
tions was a 20 ms delay after the first and third 90#{176}pulses
and a 65 ms delay after the second 90#{176}pulse. Immediately
after MRI lungs were removed, placed in 10% phosphate-
buffered formalin, processed for histology using H & E stain-
ing, and assessed by light microscopy.
Statistical analysis
Data were analyzed using ANOVA within the General
Linear Model procedure of SAS (21) with a factorial model.
When an overall F ratio was significant, the least-squares
means were used pairwise to determine significant differ-
ences. When the probability of getting a larger t value was
less than 0.05, the differences were considered significant.
The preplanned comparisons made in each time period were
between 15% treatment and each other treatment and be-
tween 0.5 and 0.5% + O’IC. Values are expressed as
means ± SEM.
RESULTS
The model of wasting malnutrition was successfully estab-
lished by feeding a diet very low in protein. Rats fed the
0.5% protein diet consumed 134.7 ± 3.4 g of feed but lost
9.1 ± 0.2 g over 2 wk, whereas rats fed the 15% protein diet
for 2 wk consumed 213.7 ± 4.8 g and gained 97.7 ± 1.1 g.
The effect of oral supplementation of OTC on tissue and
blood concentration of GSH over 24 h is shown on Fig. 1.
OTC supplementation had a significant effect on increasing
liver GSH concentration at all time points in rats fed the
0.5% protein diet but not in rats fed 15% protein diet (Fig.
IA). Rats fed the unsupplemented 0.5% protein diet had
significantly lower concentrations of GSH in the liver at all
time points than rats in the other treatment groups. OTC
supplementation had a significant effect on lung GSH con-
centration (Fig. 1B). Supplementation of O’IC to rats fed the
0.5% protein diet significantly increased lung GSH com-
pared with rats fed the 0.5% protein diet but not sup-
plemented (except at 20 h). O’IC also elevated lung GSH at
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4 and 8 h in rats fed 15% protein. However, lung GSH in
rats fed 0.5% protein, regardless of OTC supplementation,
was significantly lower than lung GSH in rats fed the 15%
protein diet. Kidney GSH concentrations were lower than in
liver and lung, and there were no significant differences in
kidney GSH concentrations among the treatment groups
(Fig. 1C). Giving oral supplementation of 01C did not have
a significant effect on GSH concentration in whole blood
(blood GSH). Blood GSH in rats fed the 0.5% protein diets
(supplemented with Olt or unsupplemented) was lower at
all time points than blood GSH in rats fed the 15% protein
diets (Fig. ID).
In experiment 2, the efficacy of OTC supplementation for
protecting against hyperoxia-induced lung damage was
evaluated. Figure 2 demonstrates the effect of OTC and
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Figure 1. Effect of oral supplementation of O’Tt on organ GSH concentration over a 24 h period in rats fed 0.5 or 15% protein diets.
Values are expressed as means ± SEM, n = 5 or 6. Significant (P < 0.05) main effects were: diet (all organs), time (liver, lung, and kid-
ney), and time x diet interaction (liver and kidney). Values marked with a star are significantly different from values in both the 0.5 and
15% groups. Values marked with an asterisk are significantly different from values in either the 0.5 or 15% group.
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Figure 2. Effect of oral supplementation of 01t and hyperoxia ex-
posure on lung-to-body weight ratios in rats fed 0.5 or 15% protein
diet. Values are expressed as means ± SEM, n = 3 or 4. Significant
(P < 0.05) main effects are diet, hyperoxia exposure, and
diet x hyperoxia exposure interaction. Values marked with a star
are significantly different from both the value in the respective air
control group and the value in the respective Olt-supplemental
group.
hyperoxia on the lung-to-body weight ratio as an index of
pulmonary oxygen toxicity in rats fed the 0.5 and 15% pro-
tein diets. Exposure to 85% oxygen for 4 days significantly
increased the percent of lung/body weight ratio in unsup-
plemented groups regardless of dietary protein level. The
lung-to-body weight ratio increased from 0.89 to 1.39% in
rats fed a 0.5% protein diet and from 0.79 to 1.29% in rats
fed a 15% protein diet. OTC supplementation reduced the
increase in lung-to-body weight ratio significantly from 1.39
to 1.00% in rats fed the 0.5% protein diet and from 1.29 to
0.81% in rats fed the 15% protein diet.
The severity of pulmonary oxygen toxicity was also evalu-
ated by in vivo proton MRI. Proton MRI is a technique for
noninvasively monitoring lung damage due to an increased
water content such as edema. Increased concentrations of
protons will appear as areas of high intensity or “bright
spots” in the image. In vivo proton MRI images of transverse
section of the upper chest cavity of rats after exposure to
hyperoxia for 4 days are shown in Fig. 3. In all treatment
groups, the absence of high-intensity proton signals in the
lung region before hyperoxia (images not shown) indicated
that there was no lung damage detectable by MRI. After 4
days of 85% oxygen exposure, the 0.5% protein group
without the OTC supplementation (Fig. 3A) had severe lung
damage as indicated by the large area of increased signal in-
tensity that appeared to outline the area occupied by the
Figure 3. In vivo proton MRI transverse images of the lung region of rats after 4 days of hyperoxia exposure (85% oxygen). Respiratory
gating was used to prevent motion artifacts caused by anatomic motion from respiration. At the top of the image or the dorsal side of
the rat, the spinal cord is represented as a bright region. The heart is not visible in these images because cardiac gating was not used.
The most severe lung damage, as indicated by the presence of increased proton signal intensity in the lung region, is observed in A (0.5%
protein) when compared with the other dietary treatments: 0.5% protein + OTC (B), 15% protein (C), and 15% protein + O1’C (D).
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lungs. VOSY was used to verify that the high intensity sig-
nals were from protons in water molecules (chemical shift
was 4.5 ppm) and not lipids. When a daily supplement of
OTC was given to rats fed 0.5% protein diet, it appeared to
prevent proton MRI-detectable, hyperoxia-induced lung
damage (Fig. 3B). By comparison, rats fed the 15% protein
diet showed minimal lung damage as monitored by proton
MRI (Fig. 3C). Daily supplementation of OTt to rats fed
the 15% protein diet may have offered some protection on
MRI-detectable, hyperoxia-induced lung damage (Fig. 3D).
Histopathological assessment by light microscopy confirmed
the evaluation of the lung damage detected by MRI (data
not shown).
Lung GSH concentrations at 0, 2, and 4 days after ex-
posure to 85% oxygen in rats fed the 0.5 or 15% protein diet
with or without OTt supplementation are shown in Table 2.
Exposure to hyperoxia for 4 days elevated lung GSH in all
treatment groups when compared with day 0 values. Daily
OTC supplementation to 0.5% protein group was effective in
elevating GSH concentration after 2 days, with a further in-
crease after 4 days of hyperoxia. Daily OTC supplementa-
tion to the 15% protein group significantly increased lung
GSH concentration after 2 days of hyperoxia exposure but
no further increase was observed after 4 days of hyperoxia.
DISCUSSION
This study demonstrated that oral administration of OTC to
wasting malnourished animals is an effective procedure to
increase GSH concentration rapidly in target organs such as
lung, and that daily supplementation of a low dose of OTC
has a sustained effect to protect against pulmonary oxygen
toxicity during 4 days of hyperoxia exposure. It has been
previously shown that OTt, a prodrug of cysteine, can be
absorbed readily and that a peak concentration can be
reached in plasma between 45 and 60 mm after a single oral
dose in healthy humans (22). It has also been shown that
OTC can increase hepatic GSH concentration, but only in
animals in which GSH has been previously depleted (14, 15).
In the current study we demonstrated that in wasting mal-
nourished animals, hepatic GSH can be restored within 4 h
and reaches a concentration beyond the reported normal
physiological maximum (8-10 tmol/g) (23, 24) with oral sup-
plementation of a single substrate (Fig. 1), without the com-
plete nutritional support of amino acids and energy. This
overshoot phenomenon of hepatic GSH synthesis has been
observed in weanling rats fed a marginally protein-deficient
(7.5%) diet for 2 wk that gained 121% of their initial body
weight (15). However, we were surprised that weanling rats
fed a diet containing practically no protein for 2 wk that lost
20% of their initial body weight were still able to respond
rapidly to OTC supplementation and maintain the ability to
synthesize GSH.
There are at least three possibilities for this overshoot
phenomenon. First, it seems that there is a high priority to
maintain the enzymes for GSH synthesis, such as ‘y-glutamyl-
cysteinyl synthetase, even in a severe catabolic state. Tateishi
et al. (25) demonstrated that treatment of actinomycin D or
cycloheximide did not inhibit the recovery of hepatic GSH
level after refeeding of rats starved for 1 or 2 days. They sug-
gested that the rapid increase in the hepatic GSH level upon
feeding starved animals did not require de novo formation of
GSH-synthesizing enzymes. In addition, they have shown a
declined GSH-degrading activity in the liver upon refeeding
rats after 24 h starvation (25). Second, it is possible that
hepatic GSH efflux is sensitive to the dietary protein level
and that the efflux mechanism is impaired during dietary
protein or energy deprivation. On the contrary, it has been
shown in rats that, during fasting, hepatic GSH effiux into
plasma has increased and the clearance rate of plasma GSH
has also increased (26). Third, the feedback inhibition of y-
glutamylcysteinyl synthetase by GSH (27) may be delayed
upon refeeding of rats after protein or energy deprivation,
but there are no direct experimental data to support this
speculation.
In addition to the increase in hepatic GSH concentration,
oral supplementation of OTt enhanced pulmonary GSH
concentration in wasting animals. However, GSH concentra-
tion in the lung was influenced mainly by the long-term
dietary protein regimen; e.g., rats fed the 0.5% protein diet
for 2 wk had lower lung GSH concentration than rats fed the
15% protein diet (Fig. 1B). This increased GSH concentra-
tion in the lung by OTC reflects the possible combined
effects of increased influx of GSH from blood and increased
endogenous synthesis of GSH. Similarly, blood GSH con-
centration is influenced mainly by protein nutritional status
(Fig. ID). As erythrocyte does not contain oxoprolinase (28),
OTt supplementation should not supply substrate directly
for endogenous synthesis of GSH in red blood cells. From
the clear differences between 0.5 and 15% protein diets (Fig.
1D), blood GSH may be a good index for long-term GSH
status affected by protein nutritional status. In fact, consis-
tently low erythrocyte GSH concentration has been used to
differentiate between kwashiorkor (predominantly protein
deficiency) and marasmus (mainly energy deficiency) in chil-
dren (6).
There were no significant differences in kidney GSH con-
centrations among the treatment groups (Fig. IC). The
values for kidney GSH concentration in this experiment are
lower than values in the literature, which range from 2.5 to
3.5 tmol/g (29). Perhaps this is because of the method of
handling, i.e., freezing and thawing, all tissue samples in this
experiment. The kidney, along with the pancreas, contains
TABLE 2. Effect of oral supplementation of OTC and hyperoxia exposure on lung GSH concentration in rats fed 0.5 or 15% protein diets
GSH, tm ollg lung weights
DayO Day 2 Day 4
0.5%
0.5% + OTC
15%
15% + OTC
2.20
3.23
4.20
3.95
± 0.12
± 0#{149}12AY
± 007AZ
± 0.09
2.10
4.78
5.15
± 0.O9
±
± 0.06k”
± 006BZ
3.00
5.93
5.00
5.20
± 0.35”
± O.l3c’
±
± 011BZ
dValues are expressed as means ± seas, n = 3 or 4. Significant (P < 0.05) main effects are diet, hyperoxia exposure, and diet x hyperoxia
exposure interaction. Values within a row not sharing the same A, B, or C are significantly different. Values within a column not sharing the same X,
Y, or Z are significantly different.
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high levels of -y-glutamyl transpeptidase that readily cleave
GSH as the tissue is thawing. In other tissues with low y-
glutamyl transpeptidase activity, such as the lung, liver, and
blood GSH is stable when stored at -80#{176}C(30).
It has been proposed that the clinical symptoms of
kwashiorkor result from a weakened defense system unable
to detoxify an increased production of free radicals from en-
dogenous noxious metabolites, infection, and toxins con-
taminating the food supply such as aflatoxin (6). Antioxidant
nutrient status - for example, vitamin E, A, carotene, Zn,
and Se - in children with kwashiorkor is generally low (6, 31)
and erythrocyte GSH concentration is characteristically low
(6, 32). Children who die soon after admission to the hospital
have the lowest levels of vitamin E, Zn, and GSH and the
highest levels of plasma ferritin and hepatic Fe (6). When
children with kwashiorkor are treated with a high-energy
diet containing high polyunsaturated fatty acids, iron, or
protein hydrolysate, there is often a high mortality rate (6,
33). Thus, immediate rehabilitation with a high-energy diet
could be contraindicated. In addition to its antioxidant func-
tion, GSH is also reported to be important in the initiation
of lymphocyte activation (34) and thus essential for host im-
munological defense. Supplementation of OTC before treat-
ment with a high-energy diet or drugs, to rapidly restore
GSH for both antioxidant and immune defense systems, may
improve the survival and recovery rate of wasted patients.
Adults with acute or chronic pulmonary diseases who re-
quire treatment with hyperoxia are often unable to maintain
an adequate food intake and show evidence of protein and
caloric malnutrition (35). Deneke et al. (36) have shown that
adult rats fed a low-protein or low-energy diet for 6 days ex-
hibit an increased susceptibility to 98% oxygen compared
with animals fed a 25% protein diet. Supplementation of the
low-protein diet with sulfur-containing amino acids cystine,
cysteine, and methionine prevented the increased oxygen
toxicity. Similarly, premature infants often require the use of
elevated oxygen concentrations in incubators due to im-
maturity of the lung. This increased oxidative stress requires
adequate defense and repair systems to prevent chronic lung
damage. However, LBW infants are at high risk due to their
limited energy reserve and low antioxidant status. The avail-
ability of the limiting substrate for GSH synthesis in prema-
ture infants may especially be reduced because the cysta-
thionase pathway that converts methionine to cysteine is not
fully developed (37). Our study showed that hyperoxia ex-
posure is a stress to weanling rats fed either the 0.5 or 15%
protein diet (Fig. 2 and Fig. 3). In this and other studies (8),
it has been demonstrated that hyperoxia also induces lung
GSH concentration in response to the oxidative stress. Daily
supplementation of a low dose of OTC during the hyperoxia
exposure was capable of further increasing lung GSH con-
centration (Table 2) and protecting lung from oxygen toxic-
ity (Fig. 2 and Fig. 3).
Various methods such as supplementation of prodrug,
precursor, or GSH itself have been used to increase GSH in
different tissues for protection against oxidative toxicity
(38-41). This may be clinically relevant, especially for those
diseases in which decreased tissue GSH is implicated. For
example, it is reported that the GSH concentrations in
plasma and lung epithelial lining fluid of HIV-seropositive
subjects are about 30 and 60%, respectively, of those in nor-
mal individuals (42). OTt has been shown to increase GSH
concentration in the liver (15), lung (Fig. 1), brain (43), and
lymphocytes (22). It is also effective in prevention of hepato-
toxicity of bromobenzene (44), acetaminophen (14, 45), and
pulmonary toxicity of hyperoxia (Fig. 2 and Fig. 3). Op-
timizing GSH status in target organs or tissues could be an
important strategy for the enhancement of detoxification
and immune functions to prevent and treat the clinical
manifestation of various diseases.
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